IXICO PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.625 GBX | -1.43% |
|
-1.43% | -31.00% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.53 for the 2024 fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -31.00% | 5.26M | - | ||
| +1.12% | 43.84B | B | ||
| +6.77% | 41.68B | B- | ||
| +45.26% | 41.25B | A | ||
| -11.96% | 27.04B | C | ||
| +6.01% | 25.53B | B- | ||
| -24.92% | 18.18B | B | ||
| -3.63% | 12.29B | C+ | ||
| +27.16% | 12.29B | C+ | ||
| +7.30% | 11.15B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IXI Stock
- Ratings IXICO plc
